Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

MLTX

MoonLake Immunotherapeutics

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • MLTXMoonLake Immunotherapeutics AG
    0Calm

    Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

    Running, no new patientsPhase 3600 patientsMain results: Jan 4, 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

15 sales (0 not pre-planned) · 0 purchases

  • Reich KristianChief Scientific Officer · Jul 27, 2026Sold 1,100 sharesabout $22 thousand · pre-planned
  • Reich KristianChief Scientific Officer · Jul 22, 2026Sold 2,448 sharesabout $49 thousand · pre-planned
  • Reich KristianChief Scientific Officer · Jul 21, 2026Sold 50,000 sharesabout $1.0 million · pre-planned
  • Reich KristianChief Scientific Officer · Jul 20, 2026Sold 43,700 sharesabout $878 thousand · pre-planned
  • Reich KristianChief Scientific Officer · Jul 15, 2026Sold 16,105 sharesabout $322 thousand · pre-planned
  • Santos da Silva JorgeChief Executive Officer · Jul 10, 2026Sold 68,289 sharesabout $1.4 million · pre-planned
  • Santos da Silva JorgeChief Executive Officer · Jul 9, 2026Sold 33,936 sharesabout $679 thousand · pre-planned
  • Santos da Silva JorgeChief Executive Officer · Jul 1, 2026Sold 47,775 sharesabout $957 thousand · pre-planned
  • Bodenstedt MatthiasChief Financial Officer · Jun 22, 2026Sold 39,120 sharesabout $862 thousand · pre-planned
  • Bodenstedt MatthiasChief Financial Officer · Jun 18, 2026Sold 2,794 sharesabout $55 thousand · pre-planned
  • Bodenstedt MatthiasChief Financial Officer · Jun 17, 2026Sold 15,082 sharesabout $297 thousand · pre-planned
  • Reich KristianChief Scientific Officer · Jun 17, 2026Sold 50,000 sharesabout $972 thousand · pre-planned
  • Reich KristianChief Scientific Officer · Jun 16, 2026Sold 50,000 sharesabout $935 thousand · pre-planned
  • Reich KristianChief Scientific Officer · Jun 15, 2026Sold 50,000 sharesabout $945 thousand · pre-planned
  • Bodenstedt MatthiasChief Financial Officer · May 11, 2026Sold 13,653 sharesabout $273 thousand · pre-planned

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • Quarterly reportQuarterly report (10-Q)Nov 4, 2026
  • Shared quarterly resultsNews report (8-K)Nov 4, 2026
  • Other newsNews report (8-K)Sep 30, 2026
  • Quarterly reportQuarterly report (10-Q)Aug 10, 2026
  • Shared quarterly results; Shared information with investorsNews report (8-K)Aug 10, 2026

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Other newsNews report (8-K)
Jul 15, 2026
  • Signed a major agreementNews report (8-K)Jun 25, 2026
  • New shares being soldNew shares being sold (424B5)Jun 24, 2026
  • New shares being soldNew shares being sold (424B5)Jun 22, 2026
  • Shared information with investors; Other newsNews report (8-K)Jun 22, 2026
  • An executive or board member joined or leftNews report (8-K)Jun 9, 2026
  • Signed a major agreementNews report (8-K)Jun 1, 2026
  • Quarterly reportQuarterly report (10-Q)May 11, 2026
  • Shared quarterly results; Shared information with investorsNews report (8-K)May 11, 2026